^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tybost (cobicistat)

    i
    Other names: GS-9350, JNJ-48763364
    Company:
    Gilead
    Drug class:
    Cytochrome P450 inhibitor
    Related drugs:
    4d
    In silico screening of potential FGF2 inhibitors for cancer therapy. (PubMed, In Silico Pharmacol)
    Molecular docking study showed Elbasvir (1) to exhibit the strongest binding affinity (-8.1 kcal/mol), followed by Velpatasvir (2) (-7.6 kcal/mol), Daclatasvir (3) (-7.5 kcal/mol), Ritonavir (4) (-6.2 kcal/mol), Paliperidone Palmitate (5) (-5.9 kcal/mol), Saralasin (6) (-5.4 kcal/mol), Nystatin (8) (-5.2 kcal/mol), and Cobicistat (-5.1 kcal/mol)...Overall, the study provides mechanistic insights into the molecular interactions between FGF2 and these candidate drugs, highlighting the promising potential of compounds 1-6 and 8 for subsequent in vitro validation in cancer therapeutics. The online version contains supplementary material available at 10.1007/s40203-025-00495-2.
    Journal
    |
    FGFR (Fibroblast Growth Factor Receptor) • FGF2 (Fibroblast Growth Factor 2)
    |
    Tybost (cobicistat) • ritonavir
    1m
    ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=175, Completed, Constellation Pharmaceuticals | Phase classification: P1b/2 --> P1/2 | Active, not recruiting --> Completed
    Trial completion • Phase classification
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tybost (cobicistat) • lirametostat (CPI-1205)
    4ms
    Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov)
    P=N/A, N=205, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed
    Trial completion
    |
    Tybost (cobicistat)
    6ms
    Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov)
    P=N/A, N=205, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial primary completion date: Apr 2025 --> Jul 2025 | Completed --> Active, not recruiting | Trial completion date: Apr 2025 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tybost (cobicistat)
    7ms
    Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov)
    P=N/A, N=205, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Apr 2025 | Trial primary completion date: Mar 2026 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Tybost (cobicistat)
    8ms
    Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov)
    P=N/A, N=205, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | N=325 --> 205
    Enrollment closed • Enrollment change
    |
    Tybost (cobicistat)
    8ms
    Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B). (PubMed, Contemp Clin Trials Commun)
    A total of 142 patients (128 patients with BRCA+, high-grade, FIGO III/IV ovarian cancer who receive olaparib as maintenance therapy; 14 patients with other approved indications for olaparib) who start olaparib treatment in line with the drug label will be randomized between the standard monotherapy of olaparib 300 mg twice daily (BID) and the boosted therapy of olaparib 100 mg BID with cobicistat 150 mg BID. Moreover, the lower costs related to the boosted therapy contribute to a durable and accessible anticancer treatment for all patients. The PROACTIVE study has been published at ClinicalTrials.gov under NCT05078671 on October 14, 2021 and at EudraCT under 2021-004032-28 on August 24, 2021.
    PK/PD data • Journal • Head-to-Head
    |
    BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib) • Tybost (cobicistat)
    8ms
    A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations (clinicaltrials.gov)
    P2, N=250, Recruiting, Fore Biotherapeutics | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    plixorafenib (FORE-8394) • Tybost (cobicistat)
    8ms
    Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib (clinicaltrials.gov)
    P1, N=15, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    plixorafenib (FORE-8394) • Tybost (cobicistat)
    9ms
    A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Volunteers. (clinicaltrials.gov)
    P1, N=28, Completed, Fore Biotherapeutics | Recruiting --> Completed
    Trial completion
    |
    plixorafenib (FORE-8394) • Tybost (cobicistat)
    9ms
    Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib (clinicaltrials.gov)
    P1, N=15, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting --> Recruiting | Trial completion date: May 2027 --> May 2026 | Trial primary completion date: Dec 2026 --> Dec 2025
    Enrollment open • Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene)
    |
    plixorafenib (FORE-8394) • Tybost (cobicistat)
    11ms
    Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (clinicaltrials.gov)
    P2/3, N=133, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tybost (cobicistat)